RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 401.9% in the 4th quarter, Holdings Channel reports. The firm owned 53,244 shares of the company’s stock after acquiring an additional 42,636 shares during the quarter. SG Americas Securities LLC’s holdings in RAPT Therapeutics were worth $84,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC grew its holdings in RAPT Therapeutics by 138.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after buying an additional 116,853 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of RAPT Therapeutics during the 2nd quarter worth $270,000. Exchange Traded Concepts LLC grew its holdings in shares of RAPT Therapeutics by 244.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock worth $179,000 after purchasing an additional 63,235 shares during the period. Barclays PLC boosted its holdings in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after acquiring an additional 25,130 shares during the period. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on RAPT shares. Wells Fargo & Company lowered their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $2.00 in a research report on Monday, November 11th. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Finally, HC Wainwright raised RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Thursday, December 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, RAPT Therapeutics has a consensus rating of “Hold” and an average price target of $9.56.

RAPT Therapeutics Trading Up 2.6 %

Shares of RAPT stock opened at $1.19 on Friday. The business’s 50 day moving average is $1.26 and its two-hundred day moving average is $1.72. RAPT Therapeutics, Inc. has a twelve month low of $0.79 and a twelve month high of $26.28. The company has a market capitalization of $41.60 million, a P/E ratio of -0.43 and a beta of 0.03.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, equities analysts predict that RAPT Therapeutics, Inc. will post -2.43 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.